SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation ...

On a video call in early September, Sarah Tabrizi first saw the data that she and other researchers studying Huntington’s ...

The inaugural competition surprisingly awarded two $100,000 grand prizes to address challenges in defining robust benchmarks for complex biology.

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, today announced that Amber Salzman, ...

An update from Targovax ASA ( ($GB:0RIS) ) is now available. Circio Holding ASA has announced a proposed rights issue to raise up to NOK 50 ...

The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...

Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...

The mammalian elongation complex has remained a mystery – until researchers discovered how it controls its speed.

To date, ETX101 has shown a favorable safety profile and has been well-tolerated across all four dose levels with no treatment-related serious adverse events (n=19). The most common treatment-related ...